IntelliPharmaCeutics Intl (IPCI) Receives Daily Media Impact Rating of -0.03
News headlines about IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) have been trending somewhat negative recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. IntelliPharmaCeutics Intl earned a coverage optimism score of -0.03 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.4533049994798 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s rankings:
- Analyst Sees Over 160% Upside for IntelliPharmaCeutics Intl Inc (USA) Stock (smarteranalyst.com)
- IntelliPharmaCeutics Intl Inc (IPCI) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- AzurRx BioPharma (AZRX) versus IntelliPharmaCeutics Intl (IPCI) Head to Head Review (americanbankingnews.com)
- $1.75 Million in Sales Expected for IntelliPharmaCeutics Intl Inc (IPCI) This Quarter (americanbankingnews.com)
Shares of IntelliPharmaCeutics Intl (NASDAQ IPCI) traded up $0.15 during midday trading on Friday, reaching $0.95. The company’s stock had a trading volume of 8,277,356 shares, compared to its average volume of 766,143. The company has a market cap of $33.12, a price-to-earnings ratio of -2.79 and a beta of 0.99. IntelliPharmaCeutics Intl has a fifty-two week low of $0.70 and a fifty-two week high of $3.12.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.